ABSTRACT
In Chapter 15, ‘Clinical and medical management of conditions caused by MDMA or “Ecstasy”’, Andrew Parrott provides an overview of the evolution of the MDMA market over the years, which has become increasingly more complex and multifaceted with the introduction of products containing very high doses of MDMA or substances passed as MDMA but actually containing a series of different products. A detailed analysis of incidences, dangers, and available treatments has been provided as well as a review of causes of death and prevention strategies. Andrew Parrott will also discuss the clinical presentation of toxicity and clinical management strategies for clinicians.
